

# **INDO-BANGLA PHARMACEUTICALS LIMITED**




**Un-Audited Financial Statements**

**For the period ended 31 March, 2025**

**INDO-BANGLA PHARMACEUTICALS LTD**  
**STATEMENT OF FINANCIAL POSITION (Un-Audited)**  
**As at 31st March, 2025**

| Particulars                                 | Notes        | Amounts in Taka      |                      |
|---------------------------------------------|--------------|----------------------|----------------------|
|                                             |              | 31st March, 2025     | 30th June 2024       |
| <b>ASSETS:</b>                              |              |                      |                      |
| <b>Non-current Assets:</b>                  |              | <b>1,305,106,403</b> | <b>1,326,160,930</b> |
| Property, Plant and Equipment               | 3.00         | 1,265,825,353        | 1,286,879,880        |
| Capital Work In Progress                    | 4.00         | 39,281,050           | 39,281,050           |
| <b>Current Assets:</b>                      |              | <b>498,701,038</b>   | <b>495,939,119</b>   |
| Inventories                                 | 5.00         | 167,557,094          | 161,590,782          |
| Trade & Other Receivables                   | 6.00         | 206,478,634          | 202,261,327          |
| Advance, Deposits and Prepayments           | 7.00         | 119,442,463          | 121,691,581          |
| Cash and Cash equivalents                   | 8.00         | 5,222,847            | 10,395,429           |
| <b>TOTAL ASSETS</b>                         |              | <b>1,803,807,441</b> | <b>1,822,100,049</b> |
| <b>EQUITY AND LIABILITIES</b>               |              |                      |                      |
| <b>Shareholders' Equity:</b>                |              | <b>1,561,191,567</b> | <b>1,580,842,948</b> |
| Share Capital                               | 9.00         | 1,162,051,780        | 1,162,051,780        |
| Retained Earnings                           | 10.00        | 399,139,787          | 418,791,168          |
| <b>NON-CURRENT LIABILITIES</b>              |              | <b>147,911,443</b>   | <b>141,103,996</b>   |
| Deferred Tax Liability                      | 11.00        | 147,911,443          | 141,103,996          |
| <b>Current Liabilities:</b>                 |              | <b>94,704,432</b>    | <b>100,153,105</b>   |
| Short Term Loan                             | 12.00        | 20,000,000           | 24,200,000           |
| Unclaimed Dividend                          | 13.00        | 14,880,368           | 14,813,593           |
| Provision for WPPF                          | 14.00        | -                    | -                    |
| Trade Payables                              | 15.00        | 195,971              | 855,971              |
| Provision for Taxes                         | 16.00        | 50,441,336           | 49,966,641           |
| Liabilities for Expenses                    | 17.00        | 9,186,757            | 10,316,900           |
| <b>Total Liabilities :</b>                  |              | <b>242,615,875</b>   | <b>241,257,101</b>   |
| <b>TOTAL OWNER'S EQUITY AND LIABILITIES</b> |              | <b>1,803,807,441</b> | <b>1,822,100,049</b> |
| <b>Net Asset Value (NAV) Per Share</b>      | <b>26.00</b> | <b>13.43</b>         | <b>13.60</b>         |

Annexed notes form an integral part of these financial statements.

 Chief Financial Officer
  Company Secretary
  Director
  Managing Director
  Chairman

Signed in terms of our separate report of even date annexed.

Place: Dhaka

Date: April 30, 2025

INDO-BANGLA PHARMACEUTICALS LTD

STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (Un-Audited)

For the third quarter ended 31st March, 2025

| Particulars                                       | Notes | Amounts in Taka                    |                                    |                                    |                                    |
|---------------------------------------------------|-------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|
|                                                   |       | 1st July 2024 to<br>31st Mar, 2025 | 1st July 2023 to<br>31st Mar, 2024 | 1st Jan, 2025 to<br>31st Mar, 2025 | 1st Jan, 2024 to<br>31st Mar, 2024 |
| Net Sales Revenue                                 | 18.00 | 76,915,773                         | 162,460,031                        | 21,889,483                         | 19,109,440                         |
| Less: Cost of Sales                               | 19.00 | 69,503,850                         | 139,338,930                        | 22,529,007                         | 17,749,288                         |
| Gross Profit                                      |       | 7,411,923                          | 23,121,101                         | (639,524)                          | 1,360,152                          |
| Less: Operating Expenses:                         |       | 19,847,164                         | 29,391,649                         | 7,632,290                          | 7,805,661                          |
| Administrative Expenses                           | 20.00 | 12,857,709                         | 19,881,029                         | 4,910,745                          | 4,980,428                          |
| Financial Expenses                                | 21.00 | 3,614,963                          | 3,542,391                          | 1,116,468                          | 1,065,809                          |
| Selling & Distributing Expenses                   | 22.00 | 3,374,492                          | 5,968,229                          | 1,605,077                          | 1,759,424                          |
| Profit from Operations                            |       | (12,435,240)                       | (6,270,548)                        | (8,271,814)                        | (6,445,509)                        |
| Add: Non Operating Income:                        | 23.00 | 66,000                             | 253,810                            | 16,000                             | 115,420                            |
| Profit before Contribution to WPPF & Welfare Fund |       | (12,369,240)                       | (6,016,738)                        | (8,255,814)                        | (6,330,089)                        |
| Less: Contribution to WPPF & Welfare Fund         | 14.00 | -                                  | -                                  | -                                  | -                                  |
| Profit before Tax                                 |       | (12,369,240)                       | (6,016,738)                        | (8,255,814)                        | (6,330,089)                        |
| Less: Income Tax Expenses:                        |       | 7,282,141                          | 8,601,253                          | 2,403,686                          | 2,733,072                          |
| Current Tax                                       | 24.00 | 474,695                            | 700,602                            | 134,537                            | 99,522                             |
| Deferred Tax                                      | 11.00 | 6,807,447                          | 7,900,651                          | 2,269,149                          | 2,633,550                          |
| Net Profit for the period                         |       | (19,651,381)                       | (14,617,991)                       | (10,659,500)                       | (9,063,161)                        |
| Basic Earnings per share (EPS)                    | 25.00 | (0.17)                             | (0.13)                             | (0.09)                             | (0.08)                             |

*[Signature]*

Chief Financial Officer

*[Signature]*

Company Secretary

*[Signature]*  
Director

*[Signature]*  
Managing Director

*[Signature]*  
Chairman

Dated: Dhaka

Date: April 30, 2025



**INDO-BANGLA PHARMACEUTICALS LTD**  
**STATEMENT OF CHANGES IN EQUITY (Un-Audited)**  
**For the third Quarter ended 31st March, 2025**

| Particulars                | Share Capital | Retained Earnings | Total Equity  |
|----------------------------|---------------|-------------------|---------------|
| Balance as at 01-July-2024 | 1,162,051,780 | 418,791,168       | 1,580,842,948 |
| Net Profit for the period  | -             | (19,651,381)      | (19,651,381)  |
| Balance as at 31-Mar-2025  | 1,162,051,780 | 399,139,787       | 1,561,191,567 |

**INDO-BANGLA PHARMACEUTICALS LTD.**  
**STATEMENT OF CHANGES IN EQUITY (Un-Audited)**  
**For the third Quarter ended 31st March, 2024**

| Particulars               | Share Capital | Retained Earnings | Total Equity  |
|---------------------------|---------------|-------------------|---------------|
| Balance as at 01-07-2023  | 1,162,051,780 | 459,770,393       | 1,621,822,173 |
| Net Profit for the period | -             | (14,617,991)      | (14,617,991)  |
| Balance as at 31-03-2024  | 1,162,051,780 | 445,152,402       | 1,607,204,182 |




Chief Financial Officer      Company Secretary      Director      Managing Director      Chairman



Place: Dhaka

Date: April 30, 2025

**INDOBANGLA PHARMACEUTICALS LIMITED**  
Statement Of Cash Flows (Un-Audited)  
For the Period ended 31st March, 2025

| Particulars                                          | Amounts in Taka                |                                |
|------------------------------------------------------|--------------------------------|--------------------------------|
|                                                      | 1st July 2024 to 31st Mar,2025 | 1st July 2023 to 31st Mar,2024 |
| <b>Cash Flow from Operating Activities</b>           |                                |                                |
| Cash receipts from customers                         | 72,698,466                     | 161,097,837                    |
| Cash receipts from others income                     | 66,000                         | 253,810                        |
| Cash payment to Suppliers                            | (45,142,745)                   | (100,133,798)                  |
| Cash payment to Employees                            | (16,681,044)                   | (24,723,569)                   |
| Cash payment to Others                               | (8,608,021)                    | (13,514,103)                   |
| <b>Cash Generate from operation</b>                  | <b>2,332,656</b>               | <b>22,980,177</b>              |
| Cash payment against income Tax                      | -                              | (636,642)                      |
| <b>Net Cash from Operating Activities</b>            | <b>2,332,656</b>               | <b>22,343,535</b>              |
| <b>Cash Flow from Investing Activities</b>           |                                |                                |
| Acquisition of property, plant and equipment         | -                              | -                              |
| Receive from Sale of Land                            | -                              | -                              |
| Paid for Work In Progress                            | -                              | (10,131,097)                   |
| <b>Net Cash used in Investing Activities</b>         | <b>-</b>                       | <b>(10,131,097)</b>            |
| <b>Cash Flow from Financing Activities</b>           |                                |                                |
| Short Term Loan                                      | (4,200,000)                    | (8,600,000)                    |
| Financial Expenses                                   | (3,305,237)                    | (4,441,047)                    |
| Paid for Dividend Refund                             | -                              | -                              |
| <b>Net Cash from Financing Activities</b>            | <b>(7,505,237)</b>             | <b>(13,041,047)</b>            |
| <b>Net increase in Cash and Cash equivalents</b>     | <b>(5,172,581)</b>             | <b>(828,608)</b>               |
| Cash and Cash Equivalents at beginning of the period | 10,395,429                     | 11,303,785                     |
| <b>Cash and Cash Equivalent at end of the Period</b> | <b>5,222,848</b>               | <b>10,475,177</b>              |
| <b>Net Operating Cash Flows Per Share (NOCFPS)</b>   | <b>0.02</b>                    | <b>0.19</b>                    |




Chief Financial Officer    Company Secretary    Director    Managing Director    Chairman

Dated: Dhaka  
 Date: April 30, 2025